Lonza announced the expansion of its peptides manufacturing capacities

03-May-2005

Lonza announced the initiation of a significant investment program in the expansion of its peptides manufacturing capacities in its production site in Visp, Switzerland. The investment totals about CHF 24 million (USD 20 million). By expanding its manufacturing activities Lonza is responding to the increased demand for peptide APIs worldwide and the increasing number of new entities entering clinical phase trials.

The investment is focused on several areas of Lonza's peptides and oligonucleotides (tides) large-scale cGMP manufacturing activities. To serve customers' demand for clinical trial material the construction of a new mid-scale tides plant is planned. Additional HPLC-purification and new lyophilization equipment as well as essential items of infrastructure will be installed.

Other news from the department manufacturing

Most read news

More news from our other portals

Fighting cancer: latest developments and advances